Entera Bio Ltd. Non-operating Income/Expense

Non-operating Income/Expense of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.

Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending June 29, 2020 was $337 Thousand (a -1565.22% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense decreased by -317.42%
  • Annual Non-operating Income/Expense for 2019 was $659 Thousand (a 18.31% increase from previous year)
  • Annual Non-operating Income/Expense for 2018 was $557 Thousand (a 281.51% increase from previous year)
  • Twelve month Non-operating Income/Expense ending June 29, 2020 was $214 Thousand (a -60.37% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense decreased by -51.58% year-over-year
Trailing Non-operating Income/Expense for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$214 Thousand $540 Thousand $659 Thousand $442 Thousand
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of Entera Bio Ltd.

Most recent Non-operating Income/Expenseof ENTX including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of Entera Bio Ltd.

Entera Bio Ltd. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.34 $-0.02
2019 $0.06 $-0.16 $0.66 $0.1 $0.66
2018 $-0.16 $-2.2 $2.92 $0.0 $0.56
2017 $0.15

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.